John Clark, MD
Pulmonary Disease · Anchorage, AKNPI 1518936871
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $670 of the $975 with a category attached, or 68.7%. 9 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 24.5% of the total. Reporting peaked in 2024 at $336 and has fallen 94.9% since, to $17 in 2025.
Across 15 payments — averaging $65.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$239
- Insmed, Inc.$199
- Sanofi$141
- AstraZeneca$101
- United Therapeutics Corporation$86
- Regeneron Healthcare Solutions, Inc.$81
- plus $129 from 3 others
What the payments were for
- Food & beverage$67069%
- Education$30631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 3 | $239 |
| Insmed, Inc. | 2 | $199 |
| Sanofi | 2 | $141 |
| AstraZeneca | 2 | $101 |
| United Therapeutics Corporation | 1 | $86 |
| Regeneron Healthcare Solutions, Inc. | 1 | $81 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Amgen | 2 | $26 |
| Pulmonx Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pulmonary disease providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 21 | $94,054 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $29,258 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $13,064 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,015 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,451 |
| Azithromycin | 124 | $1,027 |
| Doxycycline Hyclate | 22 | $299 |
| Omeprazole | 15 | $134 |
| Prednisone | 30 | $132 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $108 |
| Famotidine | 17 | $103 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Anchorage
- Marek MartynowiczAnchorage$12K
- Dustin McLemoreAnchorage$1K
- Kent StuberAnchorage$862
- Gregory GerbothAnchorage$550
- Denise WurthAnchorage$352
- David ZielkeAnchorage$219
- Beth BakerAnchorage$74
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.